| Literature DB >> 30026316 |
Delphine Cuchet-Lourenço1, Davide Eletto1, Changxin Wu1, Vincent Plagnol2, Olivier Papapietro1, James Curtis1, Lourdes Ceron-Gutierrez3, Chris M Bacon4,5, Scott Hackett6, Badr Alsaleem7, Mailis Maes1, Miguel Gaspar1, Ali Alisaac1,8, Emma Goss1, Eman AlIdrissi9, Daniela Siegmund10, Harald Wajant10, Dinakantha Kumararatne3, Mofareh S AlZahrani9, Peter D Arkwright11, Mario Abinun12, Rainer Doffinger3, Sergey Nejentsev13.
Abstract
RIPK1 (receptor-interacting serine/threonine kinase 1) is a master regulator of signaling pathways leading to inflammation and cell death and is of medical interest as a drug target. We report four patients from three unrelated families with complete RIPK1 deficiency caused by rare homozygous mutations. The patients suffered from recurrent infections, early-onset inflammatory bowel disease, and progressive polyarthritis. They had immunodeficiency with lymphopenia and altered production of various cytokines revealed by whole-blood assays. In vitro, RIPK1-deficient cells showed impaired mitogen-activated protein kinase activation and cytokine secretion and were prone to necroptosis. Hematopoietic stem cell transplantation reversed cytokine production defects and resolved clinical symptoms in one patient. Thus, RIPK1 plays a critical role in the human immune system.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30026316 PMCID: PMC6529353 DOI: 10.1126/science.aar2641
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728